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Introduction :  Misoprostol, a cheap and stable prostaglandin E1 analogue is the most widely studied 
drug for medical management of early pregnancy loss. In Malaysia, misoprostol is licensed for the 
management of stable first trimester miscarriages less than 13 weeks by Mesyuarat Panel Kaji Semula 
Senarai Ubat KKM. Most studies involving misoprostol compares between surgical and medical 
management of first trimester miscarriage. There is no study done comparing the doses of misoprostol 
in treatment of miscarriage available. This study compares between 400mcg and 800mcg in patient 
with uncomplicated missed miscarriage. 
Objectives: To evaluate the effectiveness an and side effects profile of two different dosages of 
misoprostol 
Methodology: A randomised controlled, equivalence study comparing 400 mcg and 800 mcg 
misoprostol pervaginally on an outpatient basis. The allocated dose was repeated the next day orally if 
clinically the products of conception had not been passed. Complete miscarriage was evaluated using 
two methods: ultrasound criteria on Day 7 and clinical criteria  whereby pt having symptoms and sign 
that needed surgical management (ERPOC). Equivalence was demonstrated if the 95% confidence 
interval [CI] of the observed risk difference between the two doses for complete miscarriage lay 
between -15.0 and 15.0%. Differences in side effects  were evaluated using patient-completed 
questionnaires. 
Results : 136 women were allocated to receive 400 mcg and 132 women to 800 mcg 
misoprostol for the management of missed miscarriage. The rate of induced complete miscarriage was 
equivalent using both ultrasound criteria and clinical criteria (95% CI, P = 0.352). Following the 400 
mcg dose, the reported rate of fever was stastically lower (95% CI, p<0.001). Other side effects also 
lower with diarhhoea (95% CI, p = 0.031), tiredness (95% CI, p = 0.002) and headache(95% CI, p = 
0.042) 
Conclusion: 400 mcg is as efficacious as 800mcg in inducing complete miscarriage. It also 
showed less side effect profile with significant less fever, diarrhoea, tiredness and headache. 
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ABSTRACT  
_________________________________________ 
Introduction 
Misoprostol, a cheap and stable prostaglandin E1 analogue is the most widely studied drug 
for medical management of early pregnancy loss. In Malaysia, misoprostol is licensed for the 
management of stable first trimester miscarriages less than 13 weeks by Mesyuarat Panel 
Kaji Semula Senarai Ubat KKM. Most studies involving misoprostol compares between 
surgical and medical management of first trimester miscarriage. There is no study done 
comparing the doses of misoprostol in treatment of miscarriage available. This study 
compares between 400mcg and 800mcg in patient with uncomplicated missed miscarriage. 
Objectives 
To evaluate the effectiveness an and side effects profile of two different dosages of 
misoprostol 
Methodology 
A randomised controlled, equivalence study comparing 400 mcg and 800 mcg misoprostol 
pervaginally on an outpatient basis. The allocated dose was repeated the next day orally if 
clinically the products of conception had not been passed. Complete miscarriage was 
evaluated using two methods: ultrasound criteria on Day 7 and clinical criteria  whereby pt 
having symptoms and sign that needed surgical management (ERPOC). Equivalence was 
demonstrated if the 95% confidence interval [CI] of the observed risk difference between the 
two doses for complete miscarriage lay between -15.0 and 15.0%. Differences in side effects  
were evaluated using patient-completed questionnaires. 
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RESULTS 
136 women were allocated to receive 400 mcg and 132 women to 800 mcg misoprostol for 
the management of missed miscarriage. The rate of induced complete miscarriage was 
equivalent using both ultrasound criteria and clinical criteria (95% CI, P = 0.352). Following 
the 400 mcg dose, the reported rate of fever was stastically lower (95% CI, p<0.001). Othe 
side effects also lower with diarhhoea (95% CI, p = 0.031), tiredness (95% CI, p = 0.002) and 
headache(95% CI, p = 0.042) 
Conclusion 
400 mcg is as efficacious as 800mcg in inducing complete miscarriage. It also showed less 
side effect profile with significant less fever, diarrhoea, tiredness and headache. 
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ABSTRAK    
_________________________________________ 
Pendahuluan 
Misoprostol adalah prostaglandin E1 analogue yang stabil, murah dan merupakan ubat yang 
paling banyak dikaji dalam rawatan keguguran awal kandungan melalui kaedah perubatan. Di 
Malaysia penggunaan misoprostol yang telah diberi kelulusan oleh Mesyuarat Panel  Kaji 
Semula Senarai Ubat KKM adalah untuk rawatan keguguran yang stabil pada usia kandungan 
kurang dari 13 minggu. Beberapa panduan mengenai dos misoprostol yang sepatutnya 
digunakan adalah berdasarkan kajian perbandingan antara kaedah surgeri dan perubatan,dan 
bukannya dari kajian perbandingan antara berlainan dos. Di sinilah kajian ini berbeza di mana 
perbandingan antara 400mcg dan 800mcg untuk rawatan keguguran akan dilakukan. 
Objektif 
Untuk membandingkan keberkesanan dan kesan sampingan antara dua dos misoprostol dalam 
rawatan keguguran awal kandungan 
Kaedah kajian 
Kajian perbandingan antara 400mcg dan 800mcg misoprostol dilakukan secara rawak dan 
sekata di klinik sakit puan.Misoprostol dengan dos yang ditentukan akan dimasukkan di 
dalam vagina pada hari pertama dan diulangi keesokannya secara oral jika tiada tanda-tanda 
keguguran janin berlaku. Keguguran lengkap ditentukan melalui kaedah bunyi ultra pada hari 
ketujuh and keperluan untuk sugeri melalui tanda-tanda klinikal. Perbandingan tentang kesan 
sampingan dilakukan melalui boring Questionnaires yang telah diberikan kepada pesakit. 
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Keputusan kajian 
Seramai 136 peserta telah ditentukan untuk menerima 400mcg dan 132 peserta yang lain 
menerima 800mcg untuk rawatan keguguran awal kandungan. Tiada perbezaan statistik  yang 
dapat dikesan melalui perbandingan keberkesanan antara dua dos ini (95% CI, P = 0.352). 
Dengan dos 400mcg,kesan sampingan demam dapat dikurangkan (95% CI, p<0.001), cirit 
birit (95% CI , p = 0.031), keletihan (95% CI , p = 0.002) dan sakit kepala(95% CI , p = 
0.042). 
Kesimpulan 
Misoprostol dengan dos 400mcg boleh disyorkan untuk rawatan keguguran awal kandungan 
di klinik sakit puan. 
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INTRODUCTION 
_________________________________________ 
Up to 20% patient with early pregnancy loss  opt for medical management (Shymaly 
et al , 2009). It involves administering a medication to induce complete miscarriage, allowing 
an expedient evacuation of the uterus compared to expectant management while avoiding 
surgical management. It is considered a promising alternative because it is also expected to 
reduce hospitalization cost.   
Misoprostol, a cheap, stable prostaglandin E1 analogue and requires no refrigeration, 
is the medication most widely studied for this purpose, despite its use in gynecological 
practice remaining ‘off label’. In Malaysia, indication of misoprostol that had been licensed 
by Mesyuarat Panel Kaji Semula Senarai Ubat KKM is for the management of stable first 
trimester miscarriages less than 13 weeks. It has been recognized as safe, effective and 
acceptable. Its efficacy depends upon the dosage and the route of administration. It can be 
administered both orally and vaginally and has been proven that more effective when 
administered vaginally. 
A number of different regimens have been dibed by various studies. This is one of the 
reason it still has not been widely implemented into clinical practice in developed counties. 
However most of the dosages recommended were based on the studies comparing surgical 
and medical management of early pregnancy loss, and not from studies comparing the doses. 
In the other hand, the recent studies comparing the doses were mostly done on all types of 
miscarriages, including inevitable and incomplete miscarriage. This study was different when 
comparison between 400mcg(the lowest dosage ever recommended) and 800mcg (the high 
dosage) were done on patient with uncomplicated missed miscarriage only. 
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Recent studies showed that 800mcg intravaginal misoprostol had successful rate of 
85% to induce complete miscarriage. IT is also noted that in 35% of patient, second dose of 
misoprostol is needed after 24 hours. Although these studies show a range of efficiency, 
higher success has been achieved when clinicians wait for 1-2 weeks after misoprostol 
administration before judging success or failure. 
Previous studies showed that self administrations of vaginal misoprostol at home is 
safe and has the advantage of avoiding an additional visit to the clinic and providing privacy, 
afamiliar atmosphere and family support for the women. I hope that, this study will contribute 
for the decision of opyimal recommended dosage of misoprostol with good efficavy and less 
side effct, and protocols for medical management of missed miscarriage with misoprostol in 
outpatient setting of Gynaecology clinic HRPZ II. 
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1 LITERITURE REVIEW 
Up to 20% patient with early pregnancy loss  opt for medical management (Shymaly 
et al , 2009). It involves administering a medication to induce complete miscarriage, allowing 
an expedient evacuation of the uterus compared to expectant management while avoiding 
surgical management (Satiriadis et al , 2005). It is considered a promising alternative because 
it is also expected to reduce hospitalization cost.   
Misoprostol, a cheap, stable prostaglandin E1 analogue and requires no refrigeration, 
is the medication most widely studied for this purpose, despite its use in gynecological 
practice remaining ‘off label’. In Malaysia, indication of misoprostol that had been licensed 
by Mesyuarat Panel Kaji Semula Senarai Ubat KKM is for the management of stable first 
trimester miscarriages less than 13 weeks. It has been recognized as safe, effective and 
acceptable (Peterson et al, 2013 and Barcelo et al,2012). Its efficacy depends upon the dosage 
and the route of administration. It can be administered both orally and vaginally and has been 
proven that more effective when administered vaginally (Meckstroth et al, 2006). 
1. CLINICAL REGIMENS   
Misoprostol  
Early studies of misoprostol used alone demonstrated rates of successful abortion of 
only 40–60% ( Creinin et al, 1994, Bugalho et al, 1996). Subsequently, Carbonell et al, 1997 
demonstrated improved success when tablets were moistened and placed vaginally. Up to 
three doses of 800 mg of misoprostol, place vaginally after moistening achieved success rates 
over 90% in gestations up to 9 weeks (Velaszo et al, 2000). In further dosing studies, 
Carbonell et al, 2001 found equal success and higher side-effects with 1000 mg, but much 
lower success (64%) with 600 mg. Initially, Carbonell’s studies involved rather elaborate 
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protocols with douching prior to tablet insertion, and regimens of repeat administration. Jain 
et al, 2000 achieved success rates of 88–94% up to 8 weeks’ gestation with simplified 
protocols using up to three doses of 800 mg of moistened, vaginal misoprostol.  Although 
less complex than Carbonell’s, these protocols still required multiple sonographic evaluations 
and visits to the clinic. Two of these trials compared 800 mg moistened vaginal misoprostol 
alone to a combination of mifepristone and misoprostol to 8 weeks’ gestation. The first study 
comparedwomen who received misoprostol alone to women who had received 600 mg 
mifepristone and 400 mg oral misoprostol in a previous study at the same clinic as part of a 
multi-centre trial in USA. Successful abortion occurred in 88% with misoprostol alone and in 
94% with the combination (Jain et al, 2000). A subsequent randomized controlled trial 
compared misoprostol alone to 200 mg mifepristone combined with 800 mg vaginal 
misoprostol, and found a success rate for the single drug of 88, versus 95.7% for the 
combination ( Jain et al, 2002). Time to complete abortion was slower, and additional doses 
of misoprostol were required more frequently with misoprostol alone. Although 
gastrointestinal and other misoprostol side-effects were similar in these trials,moistening 
tablets prior to vaginal administration has been shown to lead to increased side-effects 
(Creinin et al, 1999). 
Grading the evidence and recommendations for use of misoprostol alone is complex. 
According to US Preventative Task Force grading, level I evidence confirms that misoprostol 
alone is less effective than mifepristone plus misoprostol, suggesting a D-level 
recommendation against the use of this protocol when mifepristone is available. Although 
efficacy is lower, level I evidence supports the safety of medical abortion with one to three 
doses of 800 mg moistened vaginal misoprostol alone. Because mifepristone is unavailable or 
prohibitively expensive in many countries, the lower efficacy of misoprostol alone may be 
considered acceptable. When misoprostol alone is employed by women without the guidance 
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of a knowledgeable clinician, success rates may be lower and complications rates higher. 
Misoprostol is available in over 70 countries, is inexpensive and requires no refrigeration. For 
these reasons, an effective and simple regimen for medical abortion with misoprostol could 
benefit women who do not have access to other safe methods of abortion. 
2. FACTORS INFLUENCING EFFICACY 
Medical abortion is typically considered a success when a woman passes the 
pregnancy after medications and does not require surgical uterine evacuation for continuing 
pregnancy, incomplete abortion, prolonged or heavy bleeding, or patient request. In contrast, 
surgical abortion is usually considered a success if the pregnancy does not continue. Re-
aspirations for the conditions listed above are not considered failures but complications. 
Given these definitions, medical abortion has a lower overall success rate than does surgical 
abortion. With improved dosing regimens at early gestation, however, success and continuing 
pregnancy rates of medical and surgical abortion are very similar ( Child et al, 2001, 
Henshaw et al, 1994).In addition to medication factors, several patient and provider 
characteristics may affect efficacy rates of medical abortion. 
Gestational duration is an important predictor of outcome. The most recent meta-
analysis of medical abortion found that, as gestation advanced from 7 to 9 weeks, success 
rates declined from 95 to 84%. Large studies of  800 mg vaginal misoprostol achieve success 
rates over 95%, with failure due to ongoing pregnancy in only about 1% of women (Ashok et 
al,2000, 2002 and El Rafaey et al, 1994, 1995). Several large trials have reported that parous 
women have an increased failure rate compared to nulliparous women (Child et al,2001, 
Ashok et al, 2002, Schaff et al, 2000). Some studies also have noted decreased success in 
women with prior elective abortions compared to women without prior abortions. The 
reasons for these trends are unknown. One analysis found decreased success using 
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mifepristone plus a prostaglandin with increasing beta human chorionic gonadotropin (hCG) 
value and body mass index (Grimes et al,1990). Experience with medical abortion improves 
counselling and familiarizes clinicians with the course of medical abortion. When both 
patient and clinician are familiar with normal variations in bleeding, pain and other side-
effects, intervention is less frequent. This decline in surgical intervention with experience has 
been documented in studies of methotrexate (Borgatta et al, 2000), and is suggested by the 
lower success rates found in the initial US multi-centre trial, compared to countries where 
providers were experienced. 
3. PHARMACOLOGY OF MISOPROSTOL 
Misoprostol (15-deoxy-16-hydroxy-16-methyl PGE1) is a synthetic prostaglandin E1 
analogue. It was developed for the prevention and treatment of peptic ulcers because of its 
gastric acid anti-secretory properties and its various mucosal protective properties 
(Watkinson et al, 1988). It has become an important drug in obstetric and gynecological 
practice because of its uterotonic and cervical priming action. In comparison to other 
prostaglandin analogues, misoprostol has the advantages of being cheap, widely available and 
stable at room temperature and having few side effects. Its clinical applications include 
medical abortion, medical evacuation for miscarriages, cervical priming before surgical 
procedure, induction of labor and management of postpartum hemorrhage.  
STRUCTURE AND CHEMISTRY OF MISOPROSTOL 
 
Fig. 1 shows the structures of misoprostol and the naturally occurring prostaglandin E1. 
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 The naturally occurring prostaglandin E series was discovered to inhibit gastric acid 
secretion in 1967 by Robert et al. However, naturally occurring prostaglandins have three 
drawbacks that hindered their clinical application. These problems were: (1) rapid 
metabolism resulting in a lack of oral activity and a short duration of action when given 
parenterally, (2) numerous side effects, and (3) chemical instability leading to a short shelf 
life.Misoprostol differs structurally from prostaglandin E by the presence of a methyl ester at 
C-1, a methyl group at C-16 and a hydroxyl group at C-16 rather than at C-15. The methyl 
ester at C-1 increases the anti-secretory potency and duration of action of misoprostol, whilst 
the movement of the hydroxyl group from C-15 to C-16 and the addition of a methyl group at 
C-16 improves oral activity, increases the duration of action, and improves the safety profile 
of the drug. 
3.1  Pharmacokinetic properties of the various routes of administration of misoprostol. 
Misoprostol tablets were developed to be used orally. Other routes of administration, 
however, including vaginal, sublingual, buccal and rectal, have also been used extensively in 
obstetric and gynecological applications. Over the past decade there have been a number of 
studies looking at the pharmacokinetic profile of various routes of administration of 
misoprostol.  
3.2  Oral route 
         Early studies concentrated on the pharmacokinetic properties after oral administration. 
After oral administration, misoprostol is rapidly and almost completely absorbed from the 
gastrointestinal tract. However, the drug undergoes extensive and rapid first-pass metabolism 
(de-esterification) to form misoprostol acid. Following a single dose of 400 mcg oral 
misoprostol, the plasma misoprostol level increases rapidly and peaks at about 30 minutes 
declines rapidly by 120 minutes and remains low thereafter (Meckstroth et al,2006)  
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3.3  Vaginal route 
    It was found in clinical studies that vaginal administration was more effective than 
oral administration in medical abortion (El rafaey et al,1995 and Ho PC et al.1997]. Zieman 
et al performed the first pharmacokinetic study comparing oral and vaginal routes of 
administration. In contrast to the oral route, the plasma concentration increases gradually 
after vaginal administration, reaching its maximum level after 70-80 minutes before slowly 
declining with detectable drug levels still present after 6 hours. Although the peak 
concentration after oral administration is higher than for vaginal administration, the ‘area 
under the curve’ is higher when given vaginally. The greater bioavailability of vaginal 
misoprostol may help to explain why it is more effective in medical abortion. It has been 
shown that the coefficient of variation of the AUC after vaginal administration is greater than 
that after oral administration (Zieman et al,1997). This means that the vaginal absorption of 
misoprostol is inconsistent. In clinical practice, remnants of tablets are sometimes seen many 
hours after vaginal administration, indicating that the absorption is variable and incomplete. 
This may be due to the variation between women in the amount and pH of the vaginal 
discharge. Variation in the amount of bleeding during medical abortion may also affect the 
absorption of misoprostol through the vaginal mucosa. Numerous attempts have been made 
to improve the absorption of vaginal misoprostol. The addition of water to the misoprostol 
tablets is a common practice. However, this has been shown not to improve the 
bioavailability of vaginal misoprostol (Tang OS et al, 2002). 
3.4 Sublingual route 
Recently, sublingual administration of misoprostol has been studied for medical 
abortion and cervical priming. The misoprostol tablet is very soluble and can be dissolved in 
20 minutes when it is put under the tongue. A pharmacokinetic study compared the 
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absorption kinetics of oral, vaginal and sublingual routes of administration of misoprostol 
(Tang OS et al, 2002). It found that sublingual misoprostol has the shortest time to peak 
concentration, the highest peak concentration and the greatest bioavailability when compared 
to other routes.  
The peak concentration is achieved about 30 minutes after sublingual and oral 
administration, whereas following vaginal administration; it takes 75 minutes (Tang OS et al, 
2002). Therefore, it appears that the sublingual and oral routes have the quickest onset of 
action. After 400 mcg of misoprostol, a sublingual dose achieves a higher peak concentration 
than that of oral and vaginal administration. This is due to rapid absorption through the 
sublingual mucosa as well as the avoidance of the first-pass metabolism via the liver. The 
abundant blood supply under the tongue and the relatively neutral pH in the buccal cavity 
may be contributing factors. The rapid onset and high peak concentration means that of all 
the possible routes the systemic bioavailability, as measured by the AUC in the first 6 hours, 
is greatest for sublingual administration. On the other hand, although vaginal absorption has 
been shown to be slower and the peak concentrations lower than that for the other routes, the 
serum level of misoprostol is sustained at that low level for a longer period of time. In fact, at 
the end of 6 hours the serum level of misoprostol acid after vaginal administration is higher 
than those of the sublingual and oral routes. Therefore, the effect of misoprostol may linger 
for more than 6 hours after a single dose, though the threshold serum level for clinical action 
is unknown.  
3.5 . Buccal route 
Buccal administration is another way of giving misoprostol. The drug is placed 
between the teeth and the cheek and allowed to be absorbed through the buccal mucosa. 
Clinical studies, although limited compared to other routes, have shown that the buccal route 
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is also effective for medical abortion, cervical priming and labor induction (Castleman et 
al,2006 andCarlan et al,2002). The buccal route is a promising way of administering 
misoprostol and more studies are required to compare it with other routes of administration. 
3.6 Rectal route 
The rectal route of administration has been studied recently for the management of 
postpartum hemorrhage. This route of administration is less commonly used for other 
applications.  
An understanding of the pharmacokinetic properties of different routes of 
administration can help to design the best regimens for the various clinical applications. 
However, it may not be able to predict clinical outcomes for various clinical indications. 
Sublingual misoprostol, which has the shortest Tmax, is perhaps useful for clinical 
applications that require a fast onset of clinical action, such as postpartum hemorrhage or 
cervical priming. Vaginal misoprostol on the other hand, which has a high bioavailability and 
sustained serum level, is useful for indications that require a longer time for the manifestation 
of its clinical effects, like medical abortion. The absorption kinetics can also explain why 
some routes of administration are associated with a higher incidence of side effects. 
Sublingual administration, which gives the highest Cmax, is associated with highest 
incidence of side effects when compared to other routes. 
4. DOSE AND TIMING OF MISOPROSTOL 
Because side-effects increase with the dose of misoprostol, the lowest effective dose 
for each route of administration is ideal. Unfortunately, comparative dose-finding studies of 
misoprostol, used alone or in combination, are few. A comparison of misoprostol, given 
vaginally 1, 2, or 3 days after mifepristone, found no difference in efficacy (Tang OS et al, 
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2002). Some protocols require multiple doses of misoprostol after mifepristone. A second 
oral misoprostol dose appears to lead to higher overall efficacy, and may mitigate the 
influence of gestational length on efficacy with oral misoprostol (Hausknecht et al,1995 and 
Ashok et al, 2002). The ideal interval between the doses is not clear, however. A week-long 
course of oral misoprostol (400 mg twice daily), was not beneficial in reducing blood loss or 
improving efficacy ( Finer et al, 2003) 
5. PHARMACOKINETICS IN HUMAN BREAST MILK 
Breastfeeding mothers may be given misoprostol for postpartum hemorrhage 
prevention and treatment. It is important therefore to consider its potential effects on the 
fetus. However, there are very few studies on the pharmacokinetics of oral misoprostol in 
breast milk. Misoprostol were detected in breast milk within 30 minutes of oral 
administration. The peak concentration was attained in 1 hour, which is slightly slower than 
the plasma level (30 minutes). The level in breast milk rapidly drops afterwards and is 
undetectable by 4-5 hours after ingestion. The misoprostol acid level in breast milk is only 
one-third of that in the plasma (Vogel et al, 2004 and Abdel-Aleem et al,2003). There is no 
data on the pharmacokinetics of misoprostol in breast milk for non-oral routes. However, it 
would be expected that the breast milk concentration would be lower after vaginal 
administration than after oral administration, but might last longer. The effect of a short 
exposure to low levels of misoprostol to the fetus is unknown. 
6. EFFECTS ON THE UTERUS AND THE CERVIX 
The uterotonic and cervical softening effects on the female genital tract were 
considered as side effects rather than therapeutic effects when misoprostol was first 
introduced. However, it is because of these effects that misoprostol is so widely used in 
obstetric and gynecological practice today. 
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6.1  Uterus 
The effect of misoprostol on uterine contractility was well studied by Gemzell-
Danielsson et al. and Aronsson et al.. After a single dose of oral misoprostol there is an 
increase in uterine tonus ( Norman et al,1991). To produce regular contractions, however, a 
sustained plasma level of misoprostol is required and this requires repeated oral doses. The 
effect of vaginal administration of a single dose of misoprostol on uterine contractility is 
initially similar to that of oral administration: an increase in uterine tonus. However,after 1-2 
h, regular uterine contractions appear and they last at least up to 4 h after the administration 
of misoprostol . The development of regular contractions after vaginal administration may 
explain the better clinical efficacy of vaginal administration when compared to oral 
administration(Ho PC et al,1997).Recently, sublingual misoprostol was studied in first and 
second trimester medical abortion. Aronsson et al.compared the effects of misoprostol on 
uterine contractility following different routes of administration (Tang OS et al,2003). It was 
found that the increase in uterine tonus is more rapid and more pronounced following oral 
and sublingual treatment than after vaginal treatment. The mean time to increase in tonus is 8 
and 11 min for oral and sublingual administration respectively compared with 20 minutes for 
vaginal administration. 
The mean time to maximum tonus is also significantly shorter for oral and sublingual 
misoprostol compared to vaginal administration. One to two hours after the administration of 
misoprostol, the tonus begins to decrease. In the case of oral misoprostol, this is the end of 
the activity. For vaginal and sublingual treatment, however, the tonus is slowly replaced by 
regular uterine contractions. These regular uterine contractions are sustained for a longer 
period after vaginal administration than after sublingual treatment, with decreased activity 
occurring only after 4 hours (compared to 3 hours with sublingual).  
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The uterine effect of buccal and rectal administration was studied by Meckstroth et al. It was 
shown that the pattern of uterine tonus and contractility of buccal administration is very 
similar to vaginal administration. Rectal administration shows the lowest uterine activity in 
terms of tonus and contractility. Furthermore the mean onset of activity was 103minutes, 
significantly longer than by other routes. This studies on uterine contractility so far have 
shown that a sustained level, rather than a high serum level, is required for the development 
of regular uterine contractions. Studies have failed to define the threshold serum level for 
uterine contractility. It seems that a very low serum level of misoprostol is required for the 
development of regular uterine contractions. This is complicated further by the fact that the 
sensitivity of the uterus to prostaglandins increases with gestation. The clinical effects or 
actions required for different indications of use also vary. The strength of contraction that is 
required to achieve the clinical effects usually increases with gestation. For instance, stronger 
contractions are required for labor induction than medial abortion. For medical abortion, the 
addition of mifepristone would certainly modify the action of misoprostol and lower the 
serum threshold level for uterine contractility. In addition to uterine contraction, the softening 
effect of misoprostol on the cervix also contributes to its clinical action. 
6.2  Cervix 
There were many clinical studies that have demonstrated the cervical priming effect 
of misoprostol in the pregnant state. Misoprostol has been used extensively for its cervical 
softening effect before induction of labor and surgical evacuation of the uterus. Studies have 
demonstrated that less force was required for mechanical dilatation of the cervix if 
misoprostol was applied before the procedure (Ngai et al,1995,Elrafaey et al,1994) While this 
softening effect on the cervix may be secondary to the uterine contractions induced by 
misoprostol, it is more likely to be due to the direct effect of misoprostol on the cervix. The 
24 
 
uterine cervix is essentially a connective tissue organ. Smooth muscle cells account for less 
that 8% of the distal part of the cervix. The exact mechanism leading to physiological 
cervical ripening is not known. The biochemical events that have been implicated in cervical 
ripening are a decrease in total collagen content, an increase in collagen solubility, and an 
increase in collagenolytic activity. Indeed, during cervical ripening there is an influx of 
inflammatory cells into the cervical stroma, which increases matrix metalloproteinases and 
thereby leads to the degradation of collagen and cervical softening . It has been proposed that 
these cells produce cytokines and prostaglandins that have an effect on extracellular matrix 
metabolism.It has also been shown that various prostaglandin analogues could decrease the 
hydroxyproline content of pregnant cervix(Rath et al,1982). 
 The histochemical changes in the pregnant cervix after misoprostol administration 
were studied using electron microscopy and proline uptake assay. The mean proline 
incorporation per mcg protein and collagen density, estimated by light intensity, was 
significantly less than the control. This indicated that the action of misoprostol appeared to be 
mainly on the connective tissue stroma with evidence of disintegration and dissolution of 
collagen (El Rafaey et al,1994). 
Most of the studies on uterine contractility and cervical softening after misoprostol 
have been conducted on pregnant women. There is, however, evidence suggesting that these 
changes alsooccur innon-pregnant uterus. Some non-pregnant women experience uterine 
cramps after misoprostol and misoprostol has been shown to also have a cervical priming 
effect in the non-pregnant state (Ziemann et al,1997). 
Misoprostol is a safe and well-tolerated drug. Pre-clinical toxicological studies 
indicate a safety margin of at least 500-1000 fold between lethal doses in animals and 
misoprostol has not been shown to be embryotoxic, fetotoxictherapeutic doses in 
